Remtolumab (ABT-122) 是一种双变量域免疫球蛋白，可以中和肿瘤坏死因子α (TNFα) 和 IL-17A。Remtolumab 显示出对 TNFα 和 IL-17A 的双重抑制。Remtolumab 可用于类风湿关节炎 (RA) 研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected weight of Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) is 198.49 kDa.

Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) is 100.00%, determined by SEC-HPLC.

Remtolumab bound to IL-17a protein, and then rebounded to secondary antibodies (human-IgG-Fc-HRP) , and read OD450. As shown in fig, Remtolumab bound to huIL-17a-His , and the EC50 was 0.072 nM.

Remtolumab bound to TNFα protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Remtolumab bound to hu-TNFα-Fc , and the EC50 was 0.027 nM.

Remtolumab bound to huTNFα-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Remtolumab bound to huTNFα-CHO-K cells, and the EC50 was 148.700 nM.

Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Remtolumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Remtolumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 0.130 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.